Pretreatment serum CRP and response to interleukin 2.

por Blay, J. Y., Négrier, S., Philip, T., Favrot, M., Mercatello, A.
Publicado 1994

Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients

por Heudel, P., Favier, B., Assaad, S., Zrounba, P., Blay, J.-Y.
Publicado en Ann Oncol (2021)

Generation of lymphokine-activated killer cells: synergy between tumor necrosis factor and interleukin 2.

por Chouaib, S, Bertoglio, J, Blay, J Y, Marchiol-Fournigault, C, Fradelizi, D
Publicado 1988

Involvement of cyclic adenosine monophosphate in the interleukin 4 inhibitory effect on interleukin 2-induced lymphokine-activated killer generation.

por Blay, J Y, Branellec, D, Robinet, E, Dugas, B, Gay, F, Chouaïb, S
Publicado 1990

Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome

por Bachelot, T, Ratel, D, Menetrier-Caux, C, Wion, D, Blay, J-Y, Berger, F
Publicado 2006

Renal cell carcinoma induces interleukin 10 and prostaglandin E(2) production by monocytes

por Ménétrier-Caux, C, Bain, C, Favrot, M C, Duc, A, Blay, J Y
Publicado 1999

Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients

por Bachelot, T, Ray-Coquard, I, Menetrier-Caux, C, Rastkha, M, Duc, A, Blay, J-Y
Publicado 2003

Targeted polytherapy in small cell sarcoma and its association with doxorubicin

por Dumont, S.N., Yang, D., Dumont, A.G., Reynoso, D., Blay, J-Y., Trent, J.C.
Publicado en Mol Oncol (2014)

Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications

por Krebs, M.G., Blay, J.-Y., Le Tourneau, C., Hong, D., Veronese, L., Antoniou, M., Bennett, I.
Publicado en ESMO Open (2021)

Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.

por Philip, T., Negrier, S., Lasset, C., Coronel, B., Bret, M., Blay, J. Y., Merrouche, Y., Carrie, C., Kaemmerlen, P., Chauvin, F.
Publicado 1993

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.

por Ravaud, A., Négrier, S., Cany, L., Merrouche, Y., Le Guillou, M., Blay, J. Y., Clavel, M., Gaston, R., Oskam, R., Philip, T.
Publicado 1994

Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas

por Ray-Coquard, I, Ghesquière, H, Bachelot, T, Borg, C, Biron, P, Sebban, C, LeCesne, A, Chauvin, F, Blay, J-Y
Publicado 2001

Multivariate analysis of prognostic factors in patients with non HIV-related primary cerebral lymphoma. A proposal for a prognostic scoring.

por Blay, J. Y., Lasset, C., Carrie, C., Chauvin, F., Coiffier, B., Gisselbrecht, C., Clavel, M., Rebattu, P., Brunat-Mentigny, M., Philip, T.
Publicado 1993

Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma.

por Négrier, S., Mercatello, A., Bret, M., Thiesse, P., Blay, J. Y., Coronel, B., Merrouche, Y., Oskam, R., Franks, C. R., Clavel, M.
Publicado 1992

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study

por Sleijfer, S, Gorlia, T, Lamers, C, Burger, H, Blay, J-Y, Le Cesne, A, Scurr, M, Collin, F, Pandite, L, Marreaud, S, Hohenberger, P
Publicado 2012

Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19

por Solodky, M.L., Galvez, C., Russias, B., Detourbet, P., N’Guyen-Bonin, V., Herr, A.-L., Zrounba, P., Blay, J.-Y.
Publicado en Ann Oncol (2020)

Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy

por Ray-Coquard, I, Borg, C, Bachelot, Th, Sebban, C, Philip, I, Clapisson, G, Le Cesne, A, Biron, P, Chauvin, F, Blay, J Y
Publicado 2003

Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma.

por Bain, C., Merrouche, Y., Puisieux, I., Blay, J. Y., Negrier, S., Bonadona, V., Lasset, C., Lanier, F., Duc, A., Gebuhrer, L., Philip, T., Favrot, M. C.
Publicado 1997

Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials

por Cesne, A L, Judson, I, Maki, R, Grosso, F, Schuetze, S, Mehren, M V, Chawla, S P, Demetri, G D, Nieto, A, Tanovic, A, Blay, J-Y
Publicado 2013

A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients

por Bachelot, T, Gomez, F, Biron, P, Ray-Coquard, I, Soler-Michel, P, Philip, I, Guastalla, J P, Rebattu, P, Dumortier, A, Droz, J P, Blay, J Y
Publicado 2002